7 Rheumatology Headlines You Missed in October 2025
October 2025 highlighted significant advances shared at the 2025 ACR Convergence, covering key updates in systemic lupus erythematosus (SLE), lupus nephritis (LN), rheumatoid arthritis (RA), Sjögren disease (SjD), and psoriatic arthritis (PsA).
Key Therapeutic Developments
- New data emphasized progress with both established and emerging therapies across multiple rheumatic conditions.
- Dual B-cell targeting showed promise for SLE and SjD treatment approaches.
- Innovative T-cell and JAK pathway-targeted therapies offered improved control in RA.
- Head-to-head biologic comparisons in PsA informed advances in treatment selection strategies.
Systemic Lupus Erythematosus and Lupus Nephritis
Telitacicept and obinutuzumab emerged as strong disease-modifying agents in SLE and LN, showing robust clinical benefits.
Rheumatoid Arthritis
Rosnilimab and upadacitinib provided evidence for enhanced, upstream disease control and improved sequencing after TNF inhibitor failure.
Sjögren Disease
Both telitacicept and monthly ianalumab treatments delivered meaningful improvements in disease activity and patient-reported outcomes.
Psoriatic Arthritis
Secukinumab demonstrated superior efficacy compared to ustekinumab in patients with prior TNF inhibitor experience, supporting new biologic treatment pathways.
The 2025 ACR Convergence data "underscored progress in both established and investigational therapies, from dual B-cell targeting in SLE and SjD to novel T-cell and JAK-targeted approaches in RA."
For a full recap of the latest rheumatology news and research from October 2025, visit HCPLive’s coverage.
Author's summary: October 2025 revealed important rheumatology advances, spotlighting new drug data across lupus, arthritis, and Sjögren’s that promise improved disease management and patient outcomes.